Join Growin Stock Community!
Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • P/E Ratio
  • P/S Ratio
  • P/B Ratio
  • EV/EBITDA
  • EV/Sales
  • PE Ratio River
ev-to-ebitda-chart

PFE EV/EBITDA

EV/EBITDA

Browsing restrictions can be lifted for a fee.

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for PFE's EV/EBITDA ratio in Q1'26 stands at 42.34, marking a significant surge from the previous quarter's value of 15.45 in Q4'25 and indicating heightened market valuation relative to earnings before interest, taxes, depreciation, and amortization. Over the period from Q2'23 to Q1'26, the EV/EBITDA ratio exhibits high volatility with an overall upward trend, starting at 9.31 in Q2'23 and peaking dramatically at 94.69 in Q2'24 before declining sharply to 11.61 in Q2'25. Notable inflection points include a rapid escalation from 14.18 in Q3'23 to 48.80 in Q1'24, followed by a correction to around 12-15 through Q3'25, suggesting periods of market optimism and subsequent normalization in PFE's valuation multiples. This area chart pattern highlights potential risks from earnings volatility or sector-specific pressures in the pharmaceutical industry.